Last Updated on March 7, 2024 by The Health Master
Schedule M
Schedule M: In the ever-evolving landscape of the pharmaceutical and nutraceutical industry, regulatory changes can send ripples of concern throughout the sector.
Recently, the Federation of Pharma Entrepreneurs (FOPE) has penned a letter to the Ministry of Health & Family Welfare, expressing deep apprehensions about the implications of the new Schedule M amendment.
This amendment mandates that manufacturing premises be exclusively dedicated to drug production, excluding any other manufacturing activities. In this article, we delve into the details of this amendment and its potential ramifications.
Understanding the Schedule M Amendment
The Restriction on Manufacturing Activities
The crux of the matter lies in the amendment’s stipulation that manufacturing premises must exclusively cater to drug production.
This restriction applies to both existing and new facilities, presenting a significant challenge for the pharmaceutical and nutraceutical industry.
International Standards vs. Schedule M
Comparative Analysis of International Regulatory Bodies
The FOPE letter highlights a disparity between the Schedule M amendment and international standards.
Regulatory bodies such as the USFDA, EU, MHRA, MCC, and TGA allow facilities to manufacture both pharmaceutical products and dietary supplements, provided they adhere to stringent standards.
Contributions to Employment and Economy
Many Indian facilities, holding approvals from local and international regulatory bodies, currently produce both pharmaceutical products and dietary supplements.
This not only contributes significantly to employment but also bolsters foreign exchange earnings and enhances consumer satisfaction.
Potential Implications of the Amendment
Dilemma in Exports
The FOPE letter forewarns that the amendment may force companies to choose between manufacturing drugs or dietary supplements, leading to potential business standstill.
This could result in losses, disruptions in exports, and damage to India’s supply chain credibility, thereby jeopardizing the “Make In India” philosophy.
Risk to India’s Global Supply Source Status
The potential fallout of the amendment extends to India’s role as a key global supply source.
The article explores how this regulatory change could hinder India’s opportunity to maintain a prominent position in the global market.
Domestic Impact of the Amendment
Disruption to Existing Facilities
FOPE’s letter outlines the impact on the Indian market, emphasizing that existing facilities, approved for both drugs and dietary supplements, may face significant disruption.
This disruption could affect the supply chain, leading to potential shortages in the Indian market.
Timeframe for Establishing New Facilities
Establishing new facilities exclusively for drug production could take up to four years.
This extended timeframe poses a risk of consumers being deprived of regularly consumed products during the transition period.
FOPE’s Plea: High Standards Deserve Continued Recognition
Adherence to Quality Standards
The industry association asserts that existing facilities, complying with high drug manufacturing standards, possess the necessary infrastructure and protocols to prevent cross-contamination.
Hence, they should be allowed to continue the production of both drugs and dietary supplements.
Urgent Call for Amendment Revocation
In a strong plea, FOPE urges the government to reconsider the amendment.
The letter underscores the industry’s commitment to maintaining high standards while emphasizing the need for flexibility in manufacturing processes.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
IPC issues Draft Pharmacovigilance Guidance Document for Pharmaceuticals
Behind the Scenes: Decoding Leadership in India’s API Industry
Illegal Plasma Trade: DCA Telangana Takes Action on Blood Centres
Ready to Use Liquid Omeprazole developed
DCA Telangana seized drugs worth Rs 5.50 lakh from Pharma Company
Drug alert: 46 out of 932 samples declared as NSQ in January 2024
A Doctor’s Legal Odyssey Under the Drugs and Cosmetics Act, 1940
Exploring Regulatory Shifts: Nutraceuticals and the Role of CDSCO
Huge quantity of medicines seized at Airport
Regulatory Actions on Indian Pharma Industry and Quality Assurance
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: